Tags

Type your tag names separated by a space and hit enter

Increased serum levels of methylglyoxal-derived hydroimidazolone-AGE are associated with increased cardiovascular disease mortality in nondiabetic women.
Atherosclerosis. 2009 Aug; 205(2):590-4.A

Abstract

OBJECTIVE

To investigate the association of the levels of methylglyoxal-derived hydroimidazolone AGE modified proteins (MG-H1-AGE) with cardiovascular disease (CVD) mortality in an 18-year follow-up study in Finnish nondiabetic and diabetic subjects.

METHODS

The study design was a nested case-control study. Serum MG-H1-AGE levels in samples drawn at baseline were measured with a DELFIA type immunoassay in 220 diabetic subjects and 61 nondiabetic subjects who died from CVD during the follow-up, and age- and gender-matched 157 diabetic subjects and 159 nondiabetic subjects who did not die from CVD.

RESULTS

In type 2 diabetic subjects serum MG-H1-AGE levels were similar in subjects who died from CVD and in subjects who did not, 32.6 (24.6-42.1) (median (interquartile range)) vs. 31.3 (22.5-40.7)U/mL (p=0.281). In nondiabetic subjects serum MG-H1 levels were significantly higher in subjects who died from CVD than in subjects who were alive, 35.4 (28.1-44.7) vs. 31.3 (24.2-38.6)U/mL (p=0.025). Corresponding MG-H1 levels were 41.2 (35.6-58.7) vs. 31.1 (26.7-35.7)U/mL, p=0.003, in women, and 34.4 (26.3-41.2) vs. 32.0 (22.8-40.3)U/mL, p=0.270, in men. Multivariate logistic regression analysis showed a significant association of serum levels of MG-H1-AGE with CVD mortality in nondiabetic women (adjusted p=0.021), but not in nondiabetic men.

CONCLUSIONS

Our 18-year follow-up study shows that high baseline serum levels of MG-H1 type of AGE modified proteins were associated with CVD mortality in nondiabetic women, but not in nondiabetic men or in diabetic subjects.

Authors+Show Affiliations

Aker and Ullevål Diabetes Research Centre, Oslo, Norway.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19185865

Citation

Kilhovd, Bente K., et al. "Increased Serum Levels of Methylglyoxal-derived hydroimidazolone-AGE Are Associated With Increased Cardiovascular Disease Mortality in Nondiabetic Women." Atherosclerosis, vol. 205, no. 2, 2009, pp. 590-4.
Kilhovd BK, Juutilainen A, Lehto S, et al. Increased serum levels of methylglyoxal-derived hydroimidazolone-AGE are associated with increased cardiovascular disease mortality in nondiabetic women. Atherosclerosis. 2009;205(2):590-4.
Kilhovd, B. K., Juutilainen, A., Lehto, S., Rönnemaa, T., Torjesen, P. A., Hanssen, K. F., & Laakso, M. (2009). Increased serum levels of methylglyoxal-derived hydroimidazolone-AGE are associated with increased cardiovascular disease mortality in nondiabetic women. Atherosclerosis, 205(2), 590-4. https://doi.org/10.1016/j.atherosclerosis.2008.12.041
Kilhovd BK, et al. Increased Serum Levels of Methylglyoxal-derived hydroimidazolone-AGE Are Associated With Increased Cardiovascular Disease Mortality in Nondiabetic Women. Atherosclerosis. 2009;205(2):590-4. PubMed PMID: 19185865.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Increased serum levels of methylglyoxal-derived hydroimidazolone-AGE are associated with increased cardiovascular disease mortality in nondiabetic women. AU - Kilhovd,Bente K, AU - Juutilainen,Auni, AU - Lehto,Seppo, AU - Rönnemaa,Tapani, AU - Torjesen,Peter A, AU - Hanssen,Kristian F, AU - Laakso,Markku, Y1 - 2009/01/09/ PY - 2008/05/26/received PY - 2008/12/20/revised PY - 2008/12/28/accepted PY - 2009/2/3/entrez PY - 2009/2/3/pubmed PY - 2009/12/16/medline SP - 590 EP - 4 JF - Atherosclerosis JO - Atherosclerosis VL - 205 IS - 2 N2 - OBJECTIVE: To investigate the association of the levels of methylglyoxal-derived hydroimidazolone AGE modified proteins (MG-H1-AGE) with cardiovascular disease (CVD) mortality in an 18-year follow-up study in Finnish nondiabetic and diabetic subjects. METHODS: The study design was a nested case-control study. Serum MG-H1-AGE levels in samples drawn at baseline were measured with a DELFIA type immunoassay in 220 diabetic subjects and 61 nondiabetic subjects who died from CVD during the follow-up, and age- and gender-matched 157 diabetic subjects and 159 nondiabetic subjects who did not die from CVD. RESULTS: In type 2 diabetic subjects serum MG-H1-AGE levels were similar in subjects who died from CVD and in subjects who did not, 32.6 (24.6-42.1) (median (interquartile range)) vs. 31.3 (22.5-40.7)U/mL (p=0.281). In nondiabetic subjects serum MG-H1 levels were significantly higher in subjects who died from CVD than in subjects who were alive, 35.4 (28.1-44.7) vs. 31.3 (24.2-38.6)U/mL (p=0.025). Corresponding MG-H1 levels were 41.2 (35.6-58.7) vs. 31.1 (26.7-35.7)U/mL, p=0.003, in women, and 34.4 (26.3-41.2) vs. 32.0 (22.8-40.3)U/mL, p=0.270, in men. Multivariate logistic regression analysis showed a significant association of serum levels of MG-H1-AGE with CVD mortality in nondiabetic women (adjusted p=0.021), but not in nondiabetic men. CONCLUSIONS: Our 18-year follow-up study shows that high baseline serum levels of MG-H1 type of AGE modified proteins were associated with CVD mortality in nondiabetic women, but not in nondiabetic men or in diabetic subjects. SN - 1879-1484 UR - https://www.unboundmedicine.com/medline/citation/19185865/Increased_serum_levels_of_methylglyoxal_derived_hydroimidazolone_AGE_are_associated_with_increased_cardiovascular_disease_mortality_in_nondiabetic_women_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0021-9150(09)00005-7 DB - PRIME DP - Unbound Medicine ER -